Main Menu

NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

BerGenBio ASA (OL: BGBIO)

 
BGBIO Technical Analysis
2.5
As on 28th Mar 2025 BGBIO STOCK Price closed @ 1.84 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 4.09 & Strong Buy for SHORT-TERM with Stoploss of 0.19 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

BGBIOSTOCK Price

Open 1.97 Change Price %
High 1.97 1 Day -0.02 -1.08
Low 1.80 1 Week 0.13 7.60
Close 1.84 1 Month -5.93 -76.32
Volume 356561 1 Year 1.72 1433.33
52 Week High 14.44 | 52 Week Low 0.11
 
OL Norway Most Active Stocks
IDEX 0.05 0.00%
BORR 40.56 0.00%
AOW 2.00 -5.21%
EAM 0.67 3.08%
NAS 11.91 -4.03%
NEL 2.43 -3.95%
ENSU 1.36 4.62%
NHY 61.66 -2.13%
SDSD 1.88 0.00%
NODL 0.23 -11.54%
 
OL Norway Top Gainers Stocks
INSR 0.18 12.50%
KOMP 5.22 9.66%
HYARD 2.94 6.91%
SKAND 1.19 6.25%
SOHO 35.00 6.06%
SOHO 35.00 6.06%
SOHO 35.00 6.06%
IOX 1.63 5.16%
HELG 163.00 4.81%
ENSU 1.36 4.62%
 
OL Norway Top Losers Stocks
ABT 5.00 -13.49%
ABT 5.00 -13.49%
ABT 5.00 -13.49%
ABT 5.00 -13.49%
ABT 5.00 -13.49%
ABT 5.00 -13.49%
NODL 0.23 -11.54%
SPOG 74.24 -9.46%
RING 379.65 -8.52%
SVEG 137.32 -7.53%
 
 
BGBIO
Daily Charts		 BGBIO
Intraday Charts		 Whats New @
Bazaartrend		 BGBIO
Free Analysis
 
BGBIO Important Levels Intraday
RESISTANCE2.17
RESISTANCE2.06
RESISTANCE2.00
RESISTANCE1.93
SUPPORT1.75
SUPPORT1.68
SUPPORT1.62
SUPPORT1.51
 
BGBIO Forecast March 2025
Share
4th UP Forecast2.13
3rd UP Forecast2.04
2nd UP Forecast1.98
1st UP Forecast1.92
1st DOWN Forecast1.76
2nd DOWN Forecast1.7
3rd DOWN Forecast1.64
4th DOWN Forecast1.55
 
BGBIO Weekly Forecast
4th UP Forecast1.96
3rd UP Forecast1.92
2nd UP Forecast1.90
1st UP Forecast1.87
1st DOWN Forecast1.81
2nd DOWN Forecast1.78
3rd DOWN Forecast1.76
4th DOWN Forecast1.72
 
BGBIO Forecast2025
4th UP Forecast32.44
3rd UP Forecast22.63
2nd UP Forecast16.56
1st UP Forecast10.49
1st DOWN Forecast-6.81
2nd DOWN Forecast-12.88
3rd DOWN Forecast-18.95
4th DOWN Forecast-28.76
 
 
BGBIO Other Details
Segment EQ
Market Capital 1643966592.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
BGBIO Address
BGBIO
 
BGBIO Latest News
 
Your Comments and Response on BerGenBio ASA
 
BGBIO Business Profile
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the developing drugs to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. The company's Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase I clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is headquartered in Bergen, Norway. Address: Jonas Lies vei 91, Bergen, Norway, 5009
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service